Name of Policy:	High Dose Pharmacotherapy			
Policy Number:	3364-160-SD-130		MEDICAL CENTER	
Department:	Psychiatry			
Approving Officer:	Chief Executive Officer - UTMC			
Responsible Agent:	Chair/Medical Director Department of Psychiatry			
	Administrative Director Department of Psychiatry		Effective Date: 06/18/2024	
Scope:	OP-Clinic-Psychiatry		Initial Effective Date: 07/2004	
New policy proposal Major revision of existing policy X Minor/technical revision of existing policy Reaffirmation of existing policy				

(A) Policy Statement

It is recognized that when caring for patients with complicated and/or severe psychiatric illness, it may be necessary to use high doses of psychotropic medications to effectively treat target symptoms.

(B) Purpose of Policy

To effectively treat target symptoms of complicated and/or severe psychiatric illness.

(C) Procedure

When it is necessary for the provider to use high doses of medications, it is expected that:

- 1. The provider is aware of the FDA-approved dosage guidelines for the medication utilized.
- 2. The provider is aware of the potential side effects and drug interactions of the medications the patient is taking, and will educate patient and/or guardian on the signs and symptoms of possible side effects.
- 3. The provider will use the lowest possible dose to effectively treat target symptoms.
- 4. The provider will obtain and document informed consent from patient and/or guardian regarding the high dose of psychotropic medications.

Approved by:		Review/Revision Date:
		08/2005
/s/		08/2007 10/02/2010
Rick Swaine, CPA Chief Executive Officer, UTMC	Date	03/04/2014 02/3/2017 09/21/2018 07/06/2021 06/18/2024
Robert Smith, MD, PhD Chair, Department of Psychiatry	Date	
/s/		
Stephanie Calmes, Ph.D., LPCC-S, LICDC-CS Administrative Director, Department of Psychiatry	Date	
Review/Revision Completed By: Agency Administration		
		Next Review Date: 06/18/2027
Policies Superseded by This Policy: ODMH-SD-130		